Ari Ezratty
Interventional Cardiology · Roslyn, NYNPI 1033197819
Payments from drug & device makers
Across 989 payments — averaging $20.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$2K
- Novartis$2K
- AstraZeneca$2K
- Boehringer Ingelheim$1K
- E.r. Squibb & Sons, L.L.C.$1K
- Johnson & Johnson$1K
- plus $10K from 31 others
What the payments were for
- Food & beverage$20,18099%
- Education$1141%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 108 | $2,220 |
| Novartis | 123 | $2,167 |
| AstraZeneca | 105 | $2,103 |
| Boehringer Ingelheim | 53 | $1,452 |
| E.r. Squibb & Sons, L.L.C. | 78 | $1,441 |
| Johnson & Johnson | 77 | $1,367 |
| Pfizer | 63 | $1,168 |
| Merck | 47 | $1,000 |
| Esperion Therapeutics, Inc. | 44 | $916 |
| Abbott | 40 | $837 |
| Sanofi-aventis U.S. LLC | 32 | $695 |
| Bayer | 16 | $667 |
| Boston Scientific | 36 | $620 |
| Novo Nordisk | 26 | $523 |
| Chiesi USA, Inc. | 19 | $335 |
| Lexicon Pharmaceuticals, Inc. | 12 | $313 |
| Daiichi Sankyo Inc. | 11 | $305 |
| Regeneron Healthcare Solutions, Inc. | 12 | $269 |
| Cvrx, Inc. | 9 | $258 |
| Arbor Pharmaceuticals, Inc. | 18 | $249 |
| Kowa Pharmaceuticals America, Inc. | 14 | $239 |
| Althera Pharmaceuticals LLC | 10 | $223 |
| Heartflow, Inc. | 6 | $149 |
| Medtronic | 1 | $105 |
| Kiniksa Pharmaceuticals, Ltd. | 5 | $101 |
| Inspire Medical Systems, Inc. | 5 | $99 |
| Lilly USA, LLC | 4 | $93 |
| Kestra Medical Technology Services, Inc. | 2 | $84 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $52 |
| GSK | 2 | $46 |
| CSL Behring | 2 | $45 |
| Alnylam Pharmaceuticals Inc. | 1 | $36 |
| Lundbeck LLC | 2 | $34 |
| Baxter Healthcare | 1 | $27 |
| Impulse Dynamics (USA) Inc. | 1 | $24 |
| Vifor Pharma, Inc. | 1 | $19 |
| Gilead | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$20,295 in reported general payments places this provider in the 60th percentile of 382 interventional cardiology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 922 | $937,833 |
| EntrestoSacubitril/Valsartan | 418 | $429,259 |
| XareltoRivaroxaban | 305 | $370,949 |
| Repatha SureclickEvolocumab | 381 | $244,827 |
| FarxigaDapagliflozin Propanediol | 80 | $94,519 |
| MultaqDronedarone Hcl | 48 | $71,850 |
| JardianceEmpagliflozin | 61 | $69,622 |
| BrilintaTicagrelor | 45 | $52,229 |
| Praluent PenAlirocumab | 87 | $48,976 |
| VascepaIcosapent Ethyl | 64 | $30,521 |
| Rosuvastatin Calcium | 1,386 | $22,656 |
| Metoprolol Succinate | 1,378 | $22,645 |
| Ezetimibe | 496 | $16,032 |
| EdarbiAzilsartan Medoxomil | 37 | $15,952 |
| Olmesartan-Amlodipine-HctzOlmesartan/Amlodipin/Hcthiazid | 90 | $14,815 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $1,168 | $937,833922 claims |
| NovartisEntresto | $2,167 | $429,259418 claims |
| Johnson & JohnsonXarelto | $1,367 | $370,949305 claims |
| AstraZenecaFarxiga, Brilinta | $2,103 | $146,748125 claims |
| Boehringer IngelheimJardiance, Tradjenta | $1,452 | $76,33574 claims |
| Sanofi-aventis U.S. LLCMultaq | $695 | $71,85048 claims |
| Arbor Pharmaceuticals, Inc.Edarbi, Edarbyclor | $249 | $29,92861 claims |
| Esperion Therapeutics, Inc.Nexlizet | $916 | $10,29113 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 382 interventional cardiology providers in New York.
Other interventional cardiology in Roslyn
- David CohenRoslyn$9.8M
- Richard ShlofmitzRoslyn$4.5M
- Evan ShlofmitzRoslyn$2.5M
- Martin LeonNew York$13.5M
- Susheel KodaliNew York$6M
- Mohamed Azeem LatibBronx$4.6M
- Deepak BhattNew York$4.1M
- Samin SharmaNew York$3.7M
- Annapoorna KiniNew York$3.5M
- Sahil ParikhNew York$2.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.